The Role of Cxcr4Hi neutrOPhils in InflueNza
Key facts
- Who runs it
- University Hospital, Bordeaux
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 90 people, planned
- Started
- Dec 2024
- Expected to end
- Dec 2026
- Type of study
- Observational, 3 groups
- Treatments tested
- Additional tubes and LBA
- Record updated
- 27 December 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Patient aged 18 yo or above
- Acute respiratory distress syndrome as defined by the Berlin classification
- Invasive mechanical ventilation for less than 24 hours
- Cause of ARDS:; Influenza infection proven by polymerase chain reaction OR; Bacterial infection (tracheal aspirate with more than 105 CFU/mL and BAL with more than 104 CFU/mL; Pancreatitis according to the 2013 Working Group IAP/APA Acute Pancreatitis Guidelines; Peritonitis according to the 2018 SFAR guidelines
- Health insurance
- Written informed consent from legal relative or representative
Who cannot take part
- Patient included in an interventional research assessing an immunomodulatory or antiviral drug
- Acquired ImmunoDeficiency Syndrome
- Neutrophils qualitative defect
- Neutropenia (< 500/mm3)
- Contraindication to BAL:; Severe bronshospasm; Out-of-control shock; Intracranial high pressure; Refractory hypoxemia (PaO2/FiO2 < 60 mmHg)
- Legal restriction: prisoners, pregnancy, legal protection
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research. Especially, there is no therapeutic strategy targeting the dysregulated host response. CXCR4-expressing neutrophils seem to be involved in the rupture of host resistance. The aim of this study is thus to compare the percentage of blood CXCR4-expressing neutrophils between influenza survivors and non-survivors.
The 3 groups in the trial
- Influenza-related ARDS group
Person with influenza virus infection proven by a positive polymerase chain reaction test for the influenza ARDS group. Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.
Treatment: Additional tubes and LBA
- Bacterial-related ARDS group
A person with a proven bacterial infection (105 colony-forming units/mL for tracheal aspirates and more than 104 colony-forming units/mL for BAL). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.
Treatment: Additional tubes and LBA
- Extra-pulmonary (digestive inflammation) ARDS group
Person presenting with acute pancreatitis according to the 2013 international recommendations (typical pain, lipasemia above 3 times normal and/or abnormality on imaging). Or Person presenting with acute bacterial peritonitis based on a clinical diagnosis and bacteria isolated on peritoneal samples (RFE SFAR 2018). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.
Treatment: Additional tubes and LBA
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Role of CXCR4-expressing Neutrophils in Influenza-related Acute Respiratory Distress Syndrome
- Record updated
- 27 December 2024